We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




LAMP Malaria Assay Evaluated in Non-Endemic Setting

By LabMedica International staff writers
Posted on 02 Nov 2017
Print article
Image: The illumigene malaria DNA amplification assay (Photo courtesy of Meridian Bioscience).
Image: The illumigene malaria DNA amplification assay (Photo courtesy of Meridian Bioscience).
Imported malaria infections in non-endemic regions remain common due to increasing travel to endemic malaria areas and population movements. Yearly approximately 10,000 cases of imported malaria are reported, but the actual number may be as high as 30,000.

Light microscopy and antigen-based rapid diagnostic tests are the primary diagnostic tools for detecting malaria, although being labor-intensive and frequently challenged by lack of personnel’s experience and low levels of parasite density. The latter is especially important in non-endemic settings.

Scientists at Ghent University Hospital (Ghent, Belgium) assessed the diagnostic performance of a malaria assay compared to microscopy, rapid diagnostic test (RDT) and real-time polymerase chain reaction (PCR). A panel of 103 stored EDTA-anticoagulated venous whole blood diagnostic samples obtained from international travelers, collected from June 2015 to June 2016, and 12 external quality control (EQC) samples were analyzed.

The objective of this study was to assess the diagnostic performance of the illumigene malaria assay, which is a qualitative in vitro diagnostic loop-mediated isothermal amplification (LAMP) test for the direct detection of Plasmodium spp. DNA in human venous EDTA whole blood samples. The assay targets a region of the Plasmodium genome that is conserved across P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi, which is a 214 bp sequence of the Plasmodium spp. mitochondrial DNA noncoding region. The assay does not distinguish between the different Plasmodium species.

The team reported that, the illumigene assay showed 100% agreement with the real-time PCR, RDT and microscopy yielding a sensitivity and specificity of 100%. Seven samples from patients recently treated for Plasmodium falciparum infection that were RDT positive and microscopy negative yielded positive test results. The performance of the illumigene assay equals that of microscopy combined with RDT in the prospective panel with three false negative RDT results and one false negative microscopy result. Excellent concordance with PCR was observed. The limit of detection of the assay approached 0.5 parasites/µL for both P. falciparum and P. vivax.

The authors concluded that in non-endemic regions where the diagnostic process for malaria infections is questioned by lack of experience and low levels of parasite densities, the illumigene assay can be of value. Due to its high sensitivity, the LAMP assay may be considered as primary diagnostic test. The study was published on October 17, 2017, in the Malaria Journal.

Related Links:
Ghent University Hospital

Gold Member
Troponin T QC
Troponin T Quality Control
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Hepatitis B Test
OnSite HBsAg Rapid Test
New
Toxoplasma Rapid Test
Toxo IgG/IgM Rapid Test Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.